Navigation Links
Fish Oil does not Appear to Protect Against Abnormal Heart Rhythms

CHICAGO - Patients with an implantable cardioverter defibrillator did not have a significantly lower risk of serious abnormal heart rhythms// or death by consuming fish oil supplements, which had been thought to have a protective effect, according to a study in the June 14 issue of JAMA.

Sudden cardiac death is responsible for approximately 50 percent of all death from cardiovascular disease in the Western world. Epidemiological studies indicate that intake of very-long-chain n-3 polyunsaturated fatty acids (omega-3 PUFAs) as present in fish or fish oil is associated with a reduction in cardiovascular death, possibly by reducing susceptibility to cardiac arrhythmia, according to background information in the article. Recent trials on fish oil and ventricular arrhythmia (abnormal heart rhythm) in patients with implantable cardioverter defibrillators (ICDs; an electrical device that can correct an abnormal heart rhythm) yielded inconclusive results.

Ingeborg A. Brouwer, Ph.D., of Wageningen University, the Netherlands, and colleagues tested the effect of omega-3 PUFAs from fish on the incidence of recurrent ventricular arrhythmia and all-cause death in a large, placebo-controlled, randomized trial of patients with ICDs. The Study on Omega-3 Fatty acids and ventricular Arrhythmia (SOFA) was conducted at 26 cardiology clinics across Europe and included 546 patients with ICDs and prior documented ventricular tachycardia (VT) or ventricular fibrillation (VF) (both are types of serious cardiac arrhythmias). Patients were randomly assigned to receive 2 grams/day of fish oil in capsules (n = 273) or placebo capsules (n = 273) for a median (midpoint) period of 356 days.

In total, 75 patients (27 percent) in the fish oil group and 81 patients (30 percent) in the placebo group received appropriate ICD intervention for VT or VF. Event-free survival did not substantially improve in the fish oil group.

"In this large randomized trial we did not find evidence of strong protective effect of intake of omega-3 PUFAs from fish oil against ventricular arrhythmia in patients with ICDs. In contrast to others, we did not find that fish oil may have proarrhythmic properties," the authors conclude.


'"/>




Related medicine news :

1. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
2. Heart Disease Sign Appears Early in Life
3. With More Appearance Conscious Consumers The Need For Slimming Products Is Rapidly Rising
4. Men Easy To Satisfy Than the Opposite Sex In Terms Of Physical Appearance
5. Grapefruit Aroma Makes Women Appear Younger
6. Bird Flu Appears In Nigeria
7. Appearance Of Facial Scars Improved By Botulinum Toxin
8. Testosterone Replacement Therapy Appears Safe for Prostate
9. Sleep Problems in Overweight Children Appear Fairly Common
10. Breast Cancer Stem Cells Appear Resistant to Radiation Therapy
11. Skin-Destroying Ulcer Appears in NSW as New Treatment Guidelines Emerge
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... , ... February 08, 2016 , ... Discover the Rocky ... over 1,400 booths and 700 companies. Attendees also get to see the most ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 14th ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua Rosenthal, ... how healthcare companies can use newly released government data on populations and physicians ... and intervene and capture the value they create to succeed in new economic ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... CITY, Calif., Feb. 8, 2016  Aoxing Pharmaceutical Company, Inc. (NYSE ... fiscal year 2016, ended December 31, 2015, the Company achieved ... recorded in the same quarter in fiscal 2015. ... in Q2 of fiscal year 2016 was $2,068,635, or $.03 ... or $.01 per share, in the Q2 of fiscal year ...
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
Breaking Medicine Technology: